Latest news with #Alnylam
Yahoo
04-08-2025
- Business
- Yahoo
Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The 5 Upgrades: Phillip Securities upgraded Spotify (SPOT) to Neutral from Reduce with an unchanged price target of $600. The firm cites the recent share pullback for the upgrade. Oppenheimer upgraded Alnylam (ALNY) to Outperform from Perform with a $490 price target. The first full quarter of Amvuttra sales in transthyretin amyloid cardiomyopathy sales beat by a sizable margin as Alnylam secured payer agreements much faster than anticipated, the firm tells investors in a research note. Wolfe Research also upgraded Alnylam to Peer Perform from Underperform and removed the firm's prior $368 price target. Baird upgraded MasTec (MTZ) to Outperform from Neutral with a price target of $210, up from $180. While the company's Q2 report wasn't great, the post-earnings selloff is overdone, the firm tells investors in a research note. Northland upgraded CommScope (COMM) to Outperform from Market Perform with a price target of $12, up from $4, citing "very strong" AI Optical datapoints last week from both hyperscale customers and peers such as Corning (GLW) that the firm says bode well for the CCS Connectivity unit. William Blair upgraded ViaSat (VSAT) to Outperform from Market Perform. The firm's sum-of-the-parts analysis indicates there is greater than 100% upside to the shares over the next year. Top 5 Downgrades: Compass Point downgraded Coinbase (COIN) to Sell from Neutral with a price target of $248, down from $330. The firm remains constructive on the current crypto cycle, but expects a "choppy" Q3 with weak August and September seasonality along with waning retail interest in crypto treasury stocks. Stifel downgraded Baxter (BAX) to Hold from Buy with a price target of $25, down from $36. Despite recent positive portfolio transformation initiatives, Baxter's "disappointing" Q2 performance, full-year guidance reduction, and the 2026 outlook leave the firm "feeling that the path to reliably consistent mid-single-digit sales growth and more-meaningful margin expansion could take longer than previously-thought," the firm tells investors. Piper Sandler downgraded AvalonBay (AVB) to Neutral from Overweight with a price target of $200, down from $255. The Q2 earnings reports in real estate thus far have shown weaker fundamentals for apartments, the firm tells investors in a research note. Piper Sandler also downgraded Essex Property Trust (ESS) to Neutral from Overweight with a price target of $275, down from $355. Stephens downgraded Cathay General (CATY) to Equal Weight from Overweight with an unchanged price target of $50. With Cathay raising its net interest margin guidance in April and net interest margin expansion having slowed materially such that NIM guidance was reiterated this quarter, the firm believes its prior upgrade rationale predicated on less-appreciated fixed asset repricing potential catalysts have "mostly played out," the firm tells investors. Wolfe Research downgraded Vera Therapeutics (VERA) to Peer Perform from Outperform without a price target. The firm sees limited near-term upside in the shares given a lack of catalysts, increasing competitive pressure and "fading" takeover prospects. Top 5 Initiations: Morgan Stanley resumed coverage of Chevron (CVX) with an Overweight rating and $174 price target. The firm believes the closing of the Hess acquisition removes an overhang on the shares and strengthens Chevron's business model. Citizens JMP initiated coverage of AeroVironment (AVAV) with an Outperform rating and $325 price target. The firm views the U.S. government's priorities, budget allocations, and new procurement mindset serve as tailwinds for AeroVironment. TD Cowen initiated coverage of Akero Therapeutics (AKRO) with a Buy rating and $76 price target. The firm believes the company's efruxifermin, an FGF21 analog, has a "differentiated" clinical profile and see commercial success in metabolic dysfunction-associated steatohepatitis. UBS initiated coverage of Pony AI (PONY) with a Buy rating and $20 price target, which implies 53% upside from current levels. Pony is best positioned for China's robotaxi commercialization, the firm tells investors in a research note. BofA initiated coverage of Liberty Formula One (FWONK) with a Neutral rating and $110 price target. The firm believes the risk/reward is balanced at current levels as strong execution over the last several years is priced into shares.
Globe and Mail
01-08-2025
- Business
- Globe and Mail
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
Alnylam Pharmaceuticals, Inc. ALNY reported second-quarter 2025 earnings of 32 cents per share, in contrast to the Zacks Consensus Estimate of a loss of 3 cents. The improvement was due to higher revenues from the sale of its lead drug, Amvuttra (vutrisiran). The company reported adjusted earnings of 56 cents in the year-ago quarter. Alnylam recorded total revenues of $773.7 million in the quarter, which easily surpassed the Zacks Consensus Estimate of $673 million. In the year-ago quarter, total revenues were $659.8. The top line rose 17% year over year on a reported basis and 16% at a constant exchange rate (CER), mainly driven by increased product sales. Net product revenues were $672.2 million, up 64% year over year on a reported basis and 62% at CER, driven by strong growth in patient demand for Amvuttra, as well as for Givlaari (givosiran) and Oxlumo (lumasiran). ALNY shares jumped 15.4% on Thursday as investors responded positively to the strong financial performance of its marketed drug portfolio. Net revenues from collaborators were $61.5 million, down 73% from the year-ago quarter, primarily due to a $185 million milestone payment received from Regeneron REGN in the year-ago quarter upon granting REGN an exclusive license to develop, manufacture and commercialize cemdisiran as a monotherapy. Furthermore, Alnylam did not recognize any revenues from Novartis NVS in the reported quarter. ALNY recognizes revenues under its ongoing collaborations with Roche RHHBY. Alnylam also recognized royalty revenues of $40 million in the reported quarter, up 78% year over year. ALNY's Q2 Results in Detail Onpattro (patisiran) is approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The injection recorded sales of $52.5 million in the reported quarter, down 32% on a reported basis. Onpattro sales beat the Zacks Consensus Estimate of $45.9 million as well as our model estimate of $46 million. Amvuttra is FDA-approved for the treatment of adult patients with polyneuropathy of hATTR amyloidosis. The European Commission also approved Amvuttra for treating hATTR amyloidosis in adult patients with stage 1 or 2 polyneuropathy. Recently, label expansion for the drug has also been approved in the United States and the EU for treating cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. Amvuttra generated sales worth $492 million in the second quarter, up 114% on a reported basis. The uptake for the product has been encouraging, with new patients starting treatment as well as several patients switching from Onpattro. The expanded label is also boosting sales. Amvuttra sales easily beat the Zacks Consensus Estimate of $365.4 million as well as our model estimate of $330.7 million. Givlaari, approved for the treatment of acute hepatic porphyria, recorded sales of $80.8 million, reflecting a year-over-year increase of 30% on a reported basis. Givlaari sales beat the Zacks Consensus Estimate of $72.6 million and our model estimate of $73.1 million. Oxlumo recorded global net product revenues of $46.9 million in the reported quarter, up 15% year over year on a reported basis. Oxlumo sales marginally beat the Zacks Consensus Estimate of $46.6 million as well as our estimate of $43.5 million. Year to date, ALNY stock has soared 66.7% compared with the industry 's 1.5% rise. Adjusted research and development (R&D) expenses gained 11% year over year to $274.1 million. R&D expenses accounted for costs associated with the startup activities for a phase III cardiovascular outcomes study, which will evaluate zilebesiran to treat patients with hypertension at high cardiovascular risk, in partnership with Roche. Expenses associated with the recently initiated phase III TRITON-CM study, evaluating nucresiran in patients with ATTR-CM, also contributed to higher R&D costs. Adjusted selling, general and administrative (SG&A) expenses increased 26% year over year to $261.2 million, primarily due to higher employee compensation costs and increased marketing investment associated with the Amvuttra launch for ATTR-CM. Cash, cash equivalents and marketable securities as of June 30, 2025, amounted to $2.86 billion compared with $2.63 billion recorded as of March 31, 2025, with the increase primarily driven by net cash inflows from operating activities and proceeds from the exercise of employee stock options. ALNY Updates 2025 Net Sales Guidance Alnylam now expects its net product revenues for Onpattro, Amvuttra, Givlaari and Oxlumo in the range of $2.65-$2.8 billion for 2025, up from the previously guided range of $2.05-$2.25 billion. The guidance for net revenues from collaborations and royalties is maintained in the range of $650-$750 million. Adjusted R&D and SG&A expenses are expected to remain in the band of $2.1-$2.2 billion. ALNY's Ongoing Collaboration Agreements Alnylam, in collaboration with Regeneron, is advancing cemdisiran, an investigational RNAi therapeutic for the treatment of complement-mediated diseases. The agreement regarding cemdisiran underwent a modification last year. Per the modified agreement, Alnylam granted exclusive rights to Regeneron to develop cemdisiran as monotherapy and in combination with anti-C5 antibodies for complement-mediated indications. ALNY regained full global development and commercialization rights to mivelsiran in all indications in 2024, after Regeneron opted out of further co-development and co-commercialization of mivelsiran in development for cerebral amyloid angiopathy and Alzheimer's disease. However, Regeneron will be eligible to receive low double-digit royalties on sales of mivelsiran, if approved. Alnylam, in collaboration with Roche, is developing zilebesiran in a mid-stage study (KARDIA-3) to treat hypertension. ALNY and RHHBY also plan to initiate a phase III cardiovascular outcomes study for the candidate by the end of 2025 for the same indication. Alnylam has granted Novartis exclusive global rights to manufacture and commercialize RNAi therapeutics targeting PCSK9, including Leqvio (inclisiran), for hypercholesterolemia and other diseases. The FDA has approved Leqvio for several heart disease indications alongside diet and statins. As of June 2025, Leqvio is approved in more than 106 countries, with ongoing late-stage studies for further label expansion. Our Take Alnylam reported better-than-expected results in the second quarter of 2025, beating earnings and revenue estimates. The year-over-year increase in revenues has been mainly fueled by growing Amvuttra sales as a result of increased patient demand. The recent label expansion of the drug for the ATTR-CM indication in the United States and the EU has further expanded the eligible patient population for the drug, which is boosting sales and is expected to continue to do so in the quarters ahead. Sales of other products, Givlaari and Oxlumo, are also contributing to the top line. ALNY's Zacks Rank Alnylam currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report
Yahoo
08-07-2025
- Health
- Yahoo
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), pozelimab-cemdisiran (Regeneron/Alnylam), and ruxaprubart (NovelMed). EXTON, PA, July 08, 2025 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or gender, though it is most commonly diagnosed in adults in their 30s and 40s. In the United States, an estimated 400 to 500 new cases are identified annually. The clinical presentation of PNH varies widely—some patients experience only mild symptoms, while others face life-threatening complications requiring interventions such as immunosuppressive therapy or blood transfusions. ¹ Hematologists are actively adapting their prescribing strategies in paroxysmal nocturnal hemoglobinuria (PNH), with future pipeline entrants poised to further reshape the treatment landscape. According to Spherix Global Insights' Q2 2025 update from RealTime Dynamix™: PNH (US), the availability and adoption of biosimilars are expected to significantly expand the overall treated PNH population—bringing more patients onto complement inhibitor therapy than ever before. The Spherix research projects that biosimilar eculizumab products—Bkemv (Amgen) and Epysqli (Teva/Samsung Bioepis)—will continue to gain traction, capturing share from both branded Soliris and Ultomiris (Alexion/AstraZeneca), as hematologists grow increasingly confident in the clinical utility and cost-effectiveness of biosimilar alternatives. Use of novel entrants in the second line is growing as well, with therapies such as Fabhalta (Novaratis) and Voydeya (AstraZeneca) capturing an increasing share of recent prescribing. These agents are selected for patients who progress or are sub-optimally controlled on C5 inhibitors. Despite these gains, access remains a major commercial hurdle. Many patients with PNH are believed to be suboptimally managed due to persistent insurance-related barriers. Nearly all prescribers report significant challenges navigating the prior authorization process, citing inconsistent payer requirements, delays in drug procurement, and a growing reliance on artificial intelligence by insurers to further restrict coverage. This evolving dynamic has become a major source of frustration for hematologists, often delaying timely access to appropriate therapies and complicating clinical decision-making. The competitive landscape in PNH continues to intensify, with future therapies gaining interest among both academic and community hematologists. The latest Spherix study incorporates target product profiles and prescriber expectations for emerging agents, including zaltenibart (Omeros), a MASP-3 inhibitor that has captured strong physician interest. Most hematologists anticipate zaltenibart will be adopted alongside existing first- and second-line therapies upon approval, driven by high efficacy expectations and its potential to address persistent unmet needs. Other late-stage candidates—such as pozelimab-cemdisiran (Regeneron/Alnylam) and ruxaprubart (NovelMed)—also register meaningful commercial and clinical potential among surveyed specialists. 'These results underscore that physicians aren't just passively watching the market evolve – they're preparing to act,' said Sarah Hendry, Hematology Franchise Head at Spherix. 'With rising expectations for access support and guideline alignment, manufacturers that combine clinical value with commercial enablement will be best positioned for success.' As was seen in Paris at the IPIG international conference when Spherix presented data from their Patient Chart Dynamix™, membership in critical professional societies is growing as hematologists seek the guidance in PNH treatments and care. The most recent release offers a comprehensive look at the U.S. PNH market, including prescribing patterns, brand dynamics, access challenges, and future projections. Delivered quarterly, RealTime Dynamix™ helps commercial teams anticipate shifts, benchmark against competitors, and support strategic planning ahead of key market events. RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts. Patient Chart Dynamix™ is an independent service that includes robust patient chart audits and integrated specialist surveys fielded biannually. This research provides an in-depth, real-world view of treatment practices by combining verified patient data with attitudinal insights from physicians. The series highlights clinical decision-making, treatment sequencing, and outcomes for targeted patient populations across key therapeutic areas. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
24-06-2025
- Health
- Time Business News
RNAi Crucial Aspects and Innovations in the RNAi Technology Market
RNA interference (RNAi) is biological process where RNA molecules inherit gene expression or translation by neutralizing targeted mRNA molecules. RNAi is crucial in regulating genes and virus protection in eukaryotic organisms. A growing prevalence of genetic disorders, rising need for therapies that target cancer, growing emphasis on neurological disorders, growing RNA interference usage in viral and infectious disease treatments, increased research and development and innovation in delivery technologies regarding RNAi technology market. Developmental regulators occur naturally as hormones or proteins which foster cellular differentiation, development, proliferation, and healing. These cells are essential for immune system control, tissue repair, and development. Key Growth Drivers and Opportunities Genetic Disorder Cases Spike: As genetic disorders become more prevalent, there is increasing demand for enhanced and specialized treatments. One of the most promising methods in this area is RNA interference (RNAi) technology. With given factors the RNAi technology will possibly be surged, generating investments, research and development and end-up with more extensive use for genetic disorder treatment. Advancement in Delivery Methods: Delivery method advancements include nanotechnology-based delivery systems and non-transgenic delivery technologies, and are estimated to mitigate delivery issues of RNAi therapeutics. Ongoing research is focusing on studying the mechanisms OD siRNA delivery and catalytic RNA vehicle development to make RNAi based cancer gene therapy having more impact. Challenges The Off-target implications which result when RNAi treatments accidently alter genes other than the intended target, restrict growth in markets. Off target effects or phenotypic results are caused by an RNAi reagent's elimination of unintended genes rather that the gene of interest. Accidental gene suppression is often referred to as an off-target effect. It develops when the RNAi molecule attaches itself to something that is not intended. Innovation and Expansion F FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B In March 2025, Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds. Alnylam's vutrisiran shows positive Phase 3 results in ATTR cardiomyopathy In June 2024, RNAi drug vutrisiran was announced by Alnylam that reduces mortality and recurrent cardiovascular events by up to 33% in patients with transthyretin amyloidosis–related cardiomyopathy, clearing the way for an upcoming NDA submission. RNAi Therapies emerge for Hereditary Transthyretin Amyloidosis (ATTR) In April 2025, The Yuzu Matcha Martini has become a new ready-to-drink bottle that was introduced by world-renowned bartender Hidetsugu Ueno in collaboration with On the Rocks Cocktails and The House of Suntory. The bottle is matched with the Japanese Boulevardier, a traditional whiskey cocktail with an Eastern touch, so it's not simply a matcha martini to add to the family's bar. Four RNAi drugs show >80% Reduction in Lipoprotein (a) In August 2024, Early-phase trials of four RNAi-based therapeutics have managed to lower plasma Lp(a) by more than 80%, and Phase 3 studies are now being conducted to assess their impact on cardiovascular outcomes. Combination mRNA+RNAi Nanoparticle Therapy for Complex Diseases In December 2024, Codedeliry of mRNA and siRNA via nanoparticles can simultaneously boost positive gene expression and mute detrimental genes, revealed to research from the University of Ottawa. This opens up fresh therapies for a range of ailments, notably cancer and heart disorders. Inventive Sparks, Expanding Markets Companies' actives in Rnai technology market includes Alnylam Pharmaceuticals, Inc., ARROWHEAD PHARMACEUTICALS, INC., Silence Therapeutics, Thermo Fisher Scientific Inc., Revvity Discovery Limited, Company, and among others. Companies for RNAi technology aim on developing safe, precise, and efficient gene-silencing therapies for broad range of rare and genetic diseases. Their goals involve getting regulatory clearances for additional indications, refining delivery methods, minimizing off-target effects, and expanding the application of RNA interference beyond liver-targeted therapies. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
19-06-2025
- Business
- Yahoo
Alnylam names Pushkal Garg as EVP, chief research and development officer
Alnylam (ALNY) Pharmaceuticals announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief Research and Development Officer to oversee an integrated R&D organization. 'I could not be more excited for Pushkal to take the helm of the combined R&D organization, given his strategic vision, operational excellence and impressive track record building and steering an industry-leading, innovative drug development organization that has delivered a new class of medicines to the world,' said Yvonne Greenstreet, M.D., CEO. Garg joined Alnylam in 2014 to build and lead the company's Development group. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ALNY: Disclaimer & DisclosureReport an Issue Alnylam price target raised to $338 from $330 at JPMorgan Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections Alnylam receives European Commission approval of AMVUTTRA Alnylam Pharma's Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
